Tysabri

Introduction The TYSABRI Observational Program (TOP) began > 10 years ago to inform on long-term safety and effectiveness of… Expand

Entyvio (vedolizumab), Takeda’s drug for inflammatory bowel disease (IBD), is in line to become the first integrin inhibitor to… Expand

INTRODUCTION Natalizumab is very effective at reducing relapses and delaying disease progression in patients with relapsing… Expand

Therapeutic monoclonal antibodies are potent new tools for a molecular targeted approach to modify the course of multiple… Expand

1061 that isn’t the problem, says ZymoGenetics chief executive Bruce Carter. Rather, it is because the acute hospitals that use… Expand

La Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS) ha recibido nueva informacion de seguridad concerniente al… Expand

The US FDA recently approved the monoclonal antibody TYSABRI (natalizumab) for use in the treatment of adults with moderately to… Expand

Although the financial implications of Elan's and Biogen Idec's shock withdrawal from the market of the highly promising multiple… Expand

The future of a promising treatment for multiple sclerosis (MS) is in question after two patients takinag the drug were diagnosed… Expand

What happens if someone else claims to have invented your invention? In the United States, only the first inventor has rights to… Expand